CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company
Ernexa Therapeutics Inc.
Sign in to watch- Ticker
- ERNA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 311103425
- Phone
- (617) 798-6700
- Business address
- 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
- Former names
- Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC
Securities
- ERNA Common Stock Nasdaq
- ERNAW Warrants Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 89 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-28 | DAmour Kevin Chief Scientific Officer | Option exercise · Restricted Stock Units | −17,573 | 52,717 | ||
| 2022-06-21 | Gurrola Sandra M Vice President of Finance | Option exercise | +8,750 | 16,953 | ||
| 2022-06-21 | Gurrola Sandra M Vice President of Finance | Shares withheld for taxes | −3,586 | $0.48 | $2K | 13,367 |
| 2022-06-21 | Gurrola Sandra M Vice President of Finance | Option exercise · Restricted Stock Units | −8,750 | 26,250 | ||
| 2022-06-03 | Jackson Andrew C. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +664,800 | 664,800 | ||
| 2022-03-11 | DAmour Kevin Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +138,400 | 138,400 | ||
| 2022-03-11 | Gurrola Sandra M Vice President of Finance | Grant or award · Stock Option (Right to buy) | +114,500 | 114,500 | ||
| 2022-03-11 | Federoff Howard J. CEO & President | Grant or award · Stock Option (Right to buy) | +413,700 | 413,700 | ||
| 2022-03-11 | Sial Jay Chief Administration Officer | Grant or award · Stock Option (Right to buy) | +117,200 | 117,200 | ||
| 2022-03-11 | Sidhu Roger Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +142,100 | 142,100 | ||
| 2022-03-11 | DAmour Kevin Chief Scientific Officer | Grant or award · Stock Option (Right to buy) | +138,400 | 138,400 | ||
| 2022-03-11 | Gurrola Sandra M Vice President of Finance | Grant or award · Stock Option (Right to buy) | +114,500 | 114,500 | ||
| 2022-03-11 | Federoff Howard J. CEO & President | Grant or award · Stock Option (Right to buy) | +413,700 | 413,700 | ||
| 2022-03-11 | Sial Jay Chief Administration Officer | Grant or award · Stock Option (Right to buy) | +117,200 | 117,200 | ||
| 2022-03-11 | Sidhu Roger Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +142,100 | 142,100 | ||
| 2022-01-14 | Redman Heather B Director | Grant or award · Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2022-01-14 | ENRIGHT ERIN S. Director | Grant or award · Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2021-12-08 | Greenwood Luba Director | Grant or award · Stock Option | +67,000 | 67,000 | ||
| 2021-12-08 | Cherington Charles Director | Grant or award · Stock Option | +67,000 | 67,000 | ||
| 2021-12-08 | Mohr Erich Director | Grant or award · Stock Option | +67,000 | 67,000 |
Page 6 of 33 · 657 trades